Overview
RIGL market data
Price History
RIGL price chart · 1M
- O
- 45.69
- H
- 46.98
- L
- 45.66
- C
- 46.85
- Vol
- 3,673.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $45.69
- Previous Close
- $46.47
- Day High
- $46.98
- Day Low
- $45.66
- 52 Week High
- $47.41
- 52 Week Low
- $25.72
- 7 Day Return
- +3.65%
- 30 Day Return
- +22.42%
- 90 Day Return
- +53.56%
- 1 Year Return
- +60.42%
- Daily Notional Volume
- $172.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 2.42 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $19.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.20 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 116.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $24.95 – $52.24 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $780.5M · P/B 1.99 · P/S 2.82.
Company News
Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49Benzinga · Aug 17, 2026, 4:13 PM
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85Benzinga · Aug 14, 2026, 5:37 PM
Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. PrescriptionBenzinga · Aug 13, 2026, 12:13 PM
8-K filing — RIGEL PHARMACEUTICALS INC (RIGL)SEC EDGAR · Aug 4, 2026, 8:10 PM
Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M EstimateBenzinga · Aug 4, 2026, 8:03 PM
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)Globenewswire Inc · Jul 29, 2026, 9:31 PM
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The AgreementBenzinga · Jun 16, 2026, 8:10 PM
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price TargetBenzinga · Jun 2, 2026, 11:02 AM